Methods for treating patients with refractory hypercholesterolemia
OwnerRobert C. PORDY, Shazia ALI +1inventors
InventorsRobert C. PORDY, Shazia ALI, Daniel A. SCHWEMMER GIPE
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating patients suffering from refractory hypercholesterolemia. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin.
Claims47
A method of treating a patient suffering from refractory hypercholesterolemia, the method comprising administering to the patient a therapeutically effective amount of a combination of (a) a statin;
- (b) a lipid-lowering agent other than a statin;
- and (c) an inhibitor of ANGPTL3.
A method for improving one or more lipid parameter(s) in a patient diagnosed with refractory hypercholesterolemia, the method comprising administering one or more therapeutically effective doses of an angiopoietin-like protein 3 (ANGPTL3) inhibitor in combination with one or more therapeutically effective doses of a lipid lowering agent selected from the group consisting of a statin, an agent that inhibits cholesterol absorption, and an agent that inhibits microsomal triglyceride transfer protein (MTTP), or a combination thereof, wherein the improvement in one or more lipid parameter(s) is one or more of the following:
- (a) a decrease from baseline (week 0) in low density lipoprotein-C (LDL-C);
- (b) a decrease from baseline in apolipoprotein B (Apo B);
- (c) a decrease from baseline in non-high high density lipoprotein-C (non-HDL-C);
- (d) a decrease from baseline in total cholesterol (total-C);
- and/or
- (e) a decrease from baseline in triglycerides (TG).
A use of a combination of a statin, one lipid lowering agent other than a statin, and an inhibitor of angiopoietin-like protein 3 (ANGPTL3) in the treatment of a patient suffering from refractory hypercholesterolemia.
A use of a combination of a statin, one lipid lowering agent other than a statin, and an inhibitor of angiopoietin-like protein 3 (ANGPTL3) in the preparation of a medicament for treating a patient suffering from refractory hypercholesterolemia.
A pharmaceutical composition for treating a patient suffering from refractory hypercholesterolemia, wherein the composition comprises a therapeutically effective amount of a combination of a statin, one lipid lowering agent other than a statin, and an inhibitor of angiopoietin-like protein 3 (ANGPTL3).
A use of an inhibitor of angiopoietin-like protein 3 (ANGPTL3) in combination with a lipid lowering agent selected from the group consisting of a statin, an agent that inhibits cholesterol absorption, and an agent that inhibits microsomal triglyceride transfer protein (MTTP), or a combination thereof, in the improvement of one or more lipid parameter(s) in a patient diagnosed with refractory hypercholesterolemia.
A use of an inhibitor of angiopoietin-like protein 3 (ANGPTL3) in combination with a lipid lowering agent selected from the group consisting of a statin, an agent that inhibits cholesterol absorption, and an agent that inhibits microsomal triglyceride transfer protein (MTTP), or a combination thereof, in the preparation of a medicament for improving one or more lipid parameter(s) in a patient diagnosed with refractory hypercholesterolemia.
A pharmaceutical composition for improving one or more lipid parameter(s) in a patient diagnosed with refractory hypercholesterolemia, wherein the composition comprises a therapeutically effective amount of an inhibitor of angiopoietin-like protein 3 (ANGPTL3) in combination with a lipid lowering agent selected from the group consisting of a statin, an agent that inhibits cholesterol absorption, and an agent that inhibits microsomal triglyceride transfer protein (MTTP), or a combination thereof.
Dependencies are inferred from the claim text.